Astrazeneca Pharma India Ltd Financials

Astrazeneca Pharma India Ltd Financial Statement

Astrazeneca Pharma India Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars	Sep 2024	Jun 2024	Mar 2024
Revenue	416.15	395.87	391.86
Operating Expense	355.46	407.01	333.81
Net Profit	38.43	-11.79	39.48
Net Profit Margin	9.23	-2.98	10.08
Earning Per Share	16.37	-4.72	15.79
EBIDTA	62.79	2.98	58.69
Effective Tax Rate	24.22	-96.50	26.74

Particulars	Sep 2024
Revenue	416.15
Operating Expense	355.46
Net Profit	38.43
Net Profit Margin	9.23
Earning Per Share	16.37
EBIDTA	62.79
Effective Tax Rate	24.22

Astrazeneca Pharma India Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Total Revenue Annual	1,295.53	1,002.97	805.60
Operating Expenses Annual	1,111.08	837.85	719.42
Operating Profit Annual	235.68	150.99	100.94
Interest Annual	1.20	0.63	0.95
Depreciation	14.81	16.26	13.31
Net Profit Annual	161.51	99.29	61.60
Tax Annual	58.03	34.81	21.44

Particulars	Mar 2024
Total Revenue Annual	1,295.53
Operating Expenses Annual	1,111.08
Operating Profit Annual	235.68
Interest Annual	1.20
Depreciation	14.81
Net Profit Annual	161.51
Tax Annual	58.03

Astrazeneca Pharma India Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Cash Flow at the Beginning	500.34	448.42	352.34
Cash Flow from Operations	27.87	58.29	100.80
Cash Flow from Investing	21.74	18.11	4.74
Cash Flow from Financing	-44.38	-24.48	-9.46
Cash Flow at the End	505.57	500.34	448.42

Particulars	Mar 2024
Cash Flow at the Beginning	500.34
Cash Flow from Operations	27.87
Cash Flow from Investing	21.74
Cash Flow from Financing	-44.38
Cash Flow at the End	505.57

Astrazeneca Pharma India Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
PBDIT Margin (%)	18.19	18.82	12.53
PBIT Margin (%)	17.04	17.20	10.43
PBT Margin (%)	2.84	-10.09	-0.54
Net PROFIT Margin (%)	12.47	9.90	7.65
Return On Networth / Equity (%)	24.84	22.95	12.73
Return On Networth /Employed (%)	33.26	30.47	16.76
Return On Assets (%)	24.31	17.52	12.31
Total Debt / Equity (X)	0.01	0.01	0.02
Asset Turnover Ratio (%)	1.95	1.77	1.61

Particulars	Mar 2024
PBDIT Margin (%)	18.19
PBIT Margin (%)	17.04
PBT Margin (%)	2.84
Net PROFIT Margin (%)	12.47
Return On Networth / Equity (%)	24.84
Return On Networth /Employed (%)	33.26
Return On Assets (%)	24.31
Total Debt / Equity (X)	0.01
Asset Turnover Ratio (%)	1.95

Astrazeneca Pharma India Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Fixed Assets Annual	66.68	68.86	74.49
Total Current Assets Annual	932.71	835.47	705.67
Non Current Assets Annual	145.32	149.40	150.89
Total Shareholders Funds Annual	711.92	588.69	511.39
Total Assets Annual	1,078.03	984.87	856.56

Particulars	Mar 2024
Fixed Assets Annual	66.68
Total Current Assets Annual	932.71
Non Current Assets Annual	145.32
Total Shareholders Funds Annual	711.92
Total Assets Annual	1,078.03

Astrazeneca Pharma India Ltd Earning Calls

No Data Availabe

Dividend Pages

PE Ratio

Get Your FAQs Right

As of Dec 26, 2024, Astrazeneca Pharma India Ltd has a market capitalization of 13,301 Cr. Value Research classifies it as a Large-Cap company.

Yes, Astrazeneca Pharma India Ltd is debt-free with a debt-to-equity ratio of 0.01.

In FY 2023 , Astrazeneca Pharma India Ltd recorded a total revenue of approximately 1,295.53 Cr marking a significant milestone in the company's financial performance.

Astrazeneca Pharma India Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.4% and 0.2% annually, respectively..

Astrazeneca Pharma India Ltd's current PE ratio is 82.35.

Astrazeneca Pharma India Ltd's ROCE averaged 25.4% from the FY ending March 2022 to 2024, with a median of 29.4%. It peaked at 30.8% in March 2024, reflecting strong capital efficiency over the period..

Astrazeneca Pharma India Ltd's latest EBIT is Rs. 220.74 Cr, surpassing the average EBIT of Rs. 146.49 Cr over the 5 years..